• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.23% Nasdaq Up1.74%

    United Therapeutics Corporation (UTHR)

    130.90 Up 1.52(1.17%) Oct 2, 3:59PM EDT
    |After Hours : 129.69 Down 1.21 (0.92%) Oct 2, 5:08PM EDT
    ProfileGet Profile for:
    United Therapeutics Corporation
    1040 Spring Street
    Silver Spring, MD 20910
    United States - Map
    Phone: 301-608-9292
    Fax: 301-608-9291
    Website: http://www.unither.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:740

    Business Summary 

    United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on United Therapeutics Corporation

    Corporate Governance 
    United Therapeutics Corporation’s ISS Governance QuickScore as of Oct 1, 2015 is 10. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 10; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Martine A. Rothblatt Ph.D., MBA, J.D., 60
    Founder, Chairman and Co-Chief Exec. Officer
    Dr. Roger A. Jeffs Ph.D., 53
    Co-Chief Exec. Officer, Pres and Director
    Mr. Paul A. Mahon J.D., 51
    Exec. VP of Strategic Planning, Gen. Counsel and Corp. Sec.
    Mr. James C. Edgemond ,
    Chief Financial Officer and Treasurer
    Dr. David Zaccardelli Pharm.D., 50
    Chief Operating Officer and Exec. VP
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders